Aquestive Therapeutics, Inc. $AQST

What the company doesAI summary of filing

Aquestive Therapeutics is a pharmaceutical company that develops and manufactures drug products using proprietary delivery technologies. The company has four licensed commercial products manufactured at its facilities and marketed by licensees globally, generating $44.5 million in revenue in 2025. Aquestive is advancing late-stage proprietary products including Anaphylm, an oral film formulation of an epinephrine prodrug for severe allergic reactions, which received a Complete Response Letter from the FDA in January 2026, and Libervant, a buccal film formulation of diazepam for seizure treatment, whose FDA approval was vacated in February 2025 due to ongoing orphan drug exclusivity litigation. The company also develops earlier-stage product candidates using its PharmFilm oral film technology platform and AdrenaVerse epinephrine prodrug platform. [10-K 2026-03-04]

Segments: Anaphylm (epinephrine prodrug sublingual film), Libervant (diazepam buccal film), Licensed products (Suboxone, Sympazan, Emylif, Ondif), AQST-108 (epinephrine topical gel)